AbbVie (NYSE: ABBV) director credited stock equivalent units from fees

Rhea-AI Filing Summary

AbbVie Inc. director Edward J. Rapp reported an acquisition of stock equivalent units tied to AbbVie stock. On 12/31/2025, 147 stock equivalent units were credited at a price of $228.49 per unit, bringing his total directly held derivative securities reported on this form to 28,498 stock equivalent units.

The units represent director fees credited to a stock equivalent unit account under a grantor trust established by the director and are paid in cash generally at age 65 or upon retirement from the board. These stock equivalent units earn the same return as if the fees were invested in AbbVie stock, and the reported balance includes units acquired through a dividend reinvestment feature.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAPP EDWARD J

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Equivalent Units	$228.49	12/31/2025		A		147		(1)	(1)	Common Stock	147	$228.49	28,498(2)	D

Explanation of Responses:

1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

	/s/ T.O. Odutayo, Attorney-in-Fact for Edward J. Rapp	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AbbVie (ABBV) disclose for director Edward J. Rapp?

The filing shows that on 12/31/2025, AbbVie director Edward J. Rapp was credited with 147 stock equivalent units tied to AbbVie stock at a price of $228.49 per unit.

How many AbbVie stock equivalent units does the reporting person hold after this transaction?

Following the reported transaction, the form lists 28,498 stock equivalent units as beneficially owned by the reporting person.

What are the stock equivalent units reported for AbbVie (ABBV) in this Form 4?

The stock equivalent units represent director fees credited to a stock equivalent unit account under a grantor trust established by the director and are designed to earn the same return as if the fees were invested in AbbVie stock.

When are the AbbVie stock equivalent units generally paid out to the director?

The filing explains that the stock equivalent units are paid in cash, generally at age 65 or upon the director’s retirement from the board.

Does the AbbVie Form 4 mention dividend reinvestment for the stock equivalent units?

Yes. The explanation states that the reported balance of 28,498 stock equivalent units includes units acquired pursuant to a dividend reinvestment feature.

What is the reporting person’s relationship to AbbVie (ABBV)?

The reporting person is identified as a Director of AbbVie Inc. on the form.